Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab(LY2062430) versus Placebo

Investigator: Adam Boxer, MD, PhD
Sponsor: Eli Lilly and Company

Location(s): United States


To test the idea that solanezumab will slow the cognitive and functional decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD. The production and deposition of amyloid plaques in the brain is thought to contribute to the development and progression of Alzheimer’s disease (AD). Solanezumab is hypothesized to reduce accumulation of amyloid plaques and thus slow the progression of AD. The primary purpose of the study is to determine if Solanezumab will slow cognitive and functional decline in participants with mild AD.